CStone Pharmaceuticals
CStone Pharmaceuticals (HKSE: 2616) is trading at HK$5.90, about ₹72 at today's HKD/INR rate, as of 30 Sep 2026, 4:08 AM ET, up 6.12% today. Indian residents can buy CStone Pharmaceuticals from India on Paasa under the RBI's Liberalised Remittance Scheme.
Quote
Today's low
HK$5.55
Today's high
HK$5.95
52 week low
HK$4.01
52 week high
HK$10.41
2616 opened at HK$5.56, closed previously at HK$5.56, and has traded between HK$4.01 and HK$10.41 over the past 52 weeks.
About
CStone Pharmaceuticals is a biopharmaceutical company dedicated to the discovery, development, and commercialization of advanced immuno-oncology and precision medicines. Its mission is to address critical unmet medical needs for cancer patients, both within China and across the globe. The company's market-ready portfolio includes Sugemalimab, a monoclonal antibody targeting programmed death ligand 1 (PD-L1); GAVRETO, an RET inhibitor approved for advanced or metastatic RET-mutant medullary and RET fusion-positive thyroid cancers; and avapritinib, a KIT/PDGFRA inhibitor used to treat adults with unresectable or metastatic gastrointestinal stromal tumors featuring a PDGFRA exon 18 mutation. CStone also maintains a strong pipeline of investigational therapies, such as Nofazinlimab (a PD-1 antibody for hepatocellular carcinoma), Ivosidenib (an isocitrate dehydrogenase 1 (IDH1) inhibitor for adults with relapsed or refractory acute myeloid leukemia with an IDH1 mutation), and Fisogatinib (an FGFR4 inhibitor for hepatocellular carcinoma). Additional pipeline assets include CS1002, CS2006, CS3002, CS3005, CS2007, CS2008, and CS500, primarily for solid tumors, along with CS5001, intended for both solid and hematologic malignancies. Established in 2015, CStone Pharmaceuticals is headquartered in Shanghai, China.
Key statistics
Avg. volume
10.77M
Market cap
HK$9.43B
P/E Ratio
-18.69
Price-to-sales ratio
19.09
Enterprise value
CN¥6.17B
Free cash flow yield
-4.99%
Debt-to-equity ratio
0.28
Return on equity
-70.82%
ROIC
-41.59%
Beta
0.25
Dividend yield
0.00%
Last dividend
HK$0.00
Financial overview
Revenue
CN¥269.58M
Earnings per share
-CN¥0.31
Free cash flow
-CN¥327.75M
Net profit margin
-98.40%
Gross margin
55.49%
EBITDA
-CN¥403.85M
Revenue growth
-33.80%
Similar securities
This is not an investment recommendation
How to buy CStone Pharmaceuticals from India
Indian residents can buy CStone Pharmaceuticals shares through Paasa in four steps. Funds leave India under the RBI's Liberalised Remittance Scheme and the shares are held in your own name with Interactive Brokers.
Open a Paasa account
Complete digital KYC with your PAN, Aadhaar and address proof. Your brokerage account is opened in your own name with Interactive Brokers.
Add funds under LRS
Transfer INR from your Indian bank account. Your bank reports the remittance under the RBI's Liberalised Remittance Scheme and converts it to US dollars and then to HKD.
Search for CStone Pharmaceuticals and place an order
Find CStone Pharmaceuticals by name or by its ticker, 2616, and choose an order type. Many Hong Kong listings trade in board lots, so the smallest order is one lot rather than one share. CStone Pharmaceuticals trades 7:00 am – 1:30 pm IST; orders can only execute during that window.
Track holdings and download tax reports
Follow your CStone Pharmaceuticals position in HKD and INR. CStone Pharmaceuticals pays no dividend today, so your filing is the capital-gains statement plus the Schedule FA holding line.
Read the full guide: how to invest in CStone Pharmaceuticals from India
Trading and taxes when buying CStone Pharmaceuticals from India
Trading and limits
- Trading hours
- 9:30 am – 4:00 pm HKT
- LRS limit
- $250,000Per financial year, under the RBI's Liberalised Remittance Scheme.
Tax for Indian residents
- TCS on remittance
- 20%Collected by your bank on LRS remittances above ₹10 lakh in a financial year. The TCS is adjustable against your income-tax liability.Adjusting TCS against your tax
- Capital gains in India
- 12.5% or slab rateGains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate.Capital gains explained
- Dividends
- NoneCStone Pharmaceuticals does not currently pay a dividend. If it starts, dividends are taxed at your slab rate in India.Dividend tax explained
Custody. Shares are held in your own name at Interactive Brokers, segregated from Paasa's own assets.
FAQs
Can Indian residents buy CStone Pharmaceuticals stock?
Yes. CStone Pharmaceuticals (2616) has been listed on the Hong Kong Stock Exchange since 2019, in the Biotechnology industry, and Indian residents can buy it through Paasa. You fund the account from your Indian bank under the RBI's Liberalised Remittance Scheme and the money is converted to US dollars and then to HKD. Shares are held in your own name at Interactive Brokers, segregated from Paasa's own assets.
How much does one CStone Pharmaceuticals share cost in rupees?
One CStone Pharmaceuticals share is HK$5.90 — about ₹72 at an HKD/INR rate of 12.24 on 29 Sep 2026. Both the CStone Pharmaceuticals price and the rupee rate move during the day, so the rupee cost changes with them.
What are the LRS and TCS rules for buying CStone Pharmaceuticals from India?
Remit up to $250,000 per financial year under the RBI's Liberalised Remittance Scheme (LRS). Banks collect 20% tax at source on LRS remittances above ₹10 lakh in a financial year; the TCS is adjustable against your income-tax liability. FX and the LRS declaration are handled by your bank when you fund your account.
What is the minimum I can buy of CStone Pharmaceuticals?
Many Hong Kong listings trade in board lots, so the smallest order is one lot rather than one share.
How are gains on CStone Pharmaceuticals shares taxed in India?
Hong Kong generally does not levy capital gains tax on non-resident individual investors for HKEX-listed stocks, so the tax is an India-side one. Gains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. The gain is computed in rupees using the HKD/INR rate on the purchase and the sale date, so the rupee move counts alongside the CStone Pharmaceuticals price. Paasa issues a capital-gains statement for your return.
Does CStone Pharmaceuticals pay a dividend?
No. CStone Pharmaceuticals does not currently pay a dividend, so holding it produces no dividend income to declare in India. If it starts paying one, the Indian treatment is the usual one — dividends are taxed at your slab rate in India — and Paasa's dividend report would show the gross amount and any tax withheld.
When can I trade CStone Pharmaceuticals from India?
The Hong Kong Stock Exchange trades 7:00 am – 1:30 pm IST in Indian time. It also halts for lunch, 9:30 am – 10:30 am IST. Orders can only execute during that window.
Is CStone Pharmaceuticals a Hong Kong SAR China company, and does that change how it is taxed?
CStone Pharmaceuticals trades on the Hong Kong Stock Exchange in HKD, but the company is domiciled in China. CStone Pharmaceuticals trades as an ordinary share listed directly in Hong Kong, not a depositary receipt. Your India-side capital-gains treatment is the same either way.
Do I have to declare CStone Pharmaceuticals shares in my Indian tax return?
Yes. Foreign shares held on 31 March must be reported in Schedule FA of your Indian income-tax return. Paasa gives you a Schedule FA-ready statement listing your CStone Pharmaceuticals holding, its cost and its closing value.
How do I sell CStone Pharmaceuticals and bring the money back to India?
You sell during market hours (7:00 am – 1:30 pm IST) and the proceeds settle in HKD in your Paasa account. From there you can hold the balance, reinvest, or repatriate. Funds can be withdrawn in any currency to any bank account in your own name. Whether the sale is short- or long-term is decided by the 24-month holding period.